Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corp (BCPC) delivers specialty performance ingredients for nutrition and industrial markets through advanced technologies. This news hub provides investors and industry professionals with essential updates on corporate developments and market leadership.
Access authoritative reporting on earnings announcements, product innovations, and strategic partnerships. Our curated collection ensures you stay informed about BCPC's advancements in microencapsulation techniques and chelation technology across human/animal nutrition sectors.
Discover press releases detailing regulatory milestones, manufacturing expansions, and sustainability initiatives. All content is verified for accuracy, offering neutral analysis without speculative commentary.
Bookmark this page for real-time access to Balchem's financial disclosures and operational updates. Regularly refreshed content supports informed decision-making for stakeholders tracking specialty chemical markets.
Balchem Corporation (NASDAQ: BCPC) has announced a conference call scheduled for April 28, 2023, at 11:00 AM ET to discuss its first-quarter results. Results will be publicly released before the market opens on the same day. The call will be led by CEO Ted Harris and CFO Martin Bengtsson, and will be available for replay until May 12, 2023. Interested parties can join the call by dialing 1-877-407-8289 or 1-201-689-8341. Balchem operates across three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, focusing on developing specialty ingredients to enhance health and well-being across various industries worldwide.
Balchem Corporation (NASDAQ: BCPC) reported impressive fourth quarter financial results for 2022, with net sales of $232.5 million, up 9.1% from $213.1 million in Q4 2021. However, net earnings decreased to $21.4 million from $24.9 million, although adjusted net earnings rose to $30.3 million from $27.8 million. For the full year, net sales increased 17.9% to a record $942.4 million, while net earnings rose 9.6% to $105.4 million. The company achieved record sales across all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Balchem also maintained a strong cash flow and continues to focus on strategic growth initiatives.
Balchem Corporation (NASDAQ: BCPC) will hold a conference call on February 24, 2023, at 11:00 AM ET to discuss its fourth quarter results. These results will be released before the market opens on the same day. The call will be hosted by Ted Harris (CEO) and Martin Bengtsson (CFO). Investors can join by dialing 1-877-407-8289, and the session will be available for replay until March 10, 2023. Balchem specializes in developing and marketing specialty ingredients across Human Nutrition, Animal Nutrition, and Specialty Products sectors, aiming to enhance health and well-being globally.
Balchem Corporation (NASDAQ: BCPC) CFO Martin Bengtsson will present at the CJS Securities 23rd Annual "New Ideas for the New Year" Investor Conference on January 11, 2023, starting at 11:00 AM EST. The presentation will be accessible on Balchem's website post-conference. Balchem specializes in developing and marketing ingredients that enhance health and well-being across various industries, with three main segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ: BCPC) announced a dividend of $0.71 per share on December 5, 2022, marking a 10.9% increase from the previous year. This dividend will be paid on January 20, 2023, to shareholders on record as of December 27, 2022. The announcement signifies the fourteenth consecutive annual dividend increase, highlighting the company's robust financial performance and the Board's confidence in its long-term strategies.
FAQ
What is the current stock price of Balchem (BCPC)?
What is the market cap of Balchem (BCPC)?
